Treatment Recommendation for 74-Year-Old Male with Gleason 7, PSA 14
For this 74-year-old man with intermediate-risk prostate cancer (Gleason 7, PSA 14), external beam radiotherapy (3D-CRT/IMRT with daily IGRT) combined with 4-6 months of androgen deprivation therapy (ADT) is the recommended treatment approach 1.
Risk Stratification
This patient falls into the intermediate-risk category based on:
- Gleason score 7
- PSA 14 ng/mL (between 10-20)
- Age 74 years
The critical distinction within Gleason 7 is whether the pattern is 3+4 versus 4+3, as this affects prognosis 2, 3. However, regardless of the primary pattern, this patient requires definitive treatment given his intermediate-risk status.
Primary Treatment Options
Preferred Approach: Radiotherapy + Short-Term ADT
Radiotherapy specifications:
- Dose: 75-80 Gy using 3D-CRT or IMRT with daily image-guided radiation therapy (IGRT) 1
- Minimum dose of 70 Gy is no longer adequate 1
- Daily prostate localization is essential for doses >75 Gy 1
ADT component:
- Duration: 4-6 months of neoadjuvant/concomitant/adjuvant ADT 1
- Three randomized trials (RTOG 8610, TROG 9601, DFCI 95096) demonstrated cancer-specific survival benefit when adding short-course ADT to external beam RT in intermediate-risk patients 1
- DFCI 95096, which included the highest proportion of intermediate-risk patients (60%), showed both overall and cancer-specific survival benefit 1
Alternative: Radical Prostatectomy
Radical prostatectomy with pelvic lymph node dissection (if predicted probability of lymph node metastasis ≥2%) is an alternative option 1. However, at age 74, several considerations make this less favorable:
- Age-related factors: The randomized trial supporting radical prostatectomy had a median age of 62 years 1, making extrapolation to a 74-year-old less certain
- Surgical morbidity: Increased risk of erectile dysfunction (80% vs 45%) and urinary leakage (49% vs 21%) compared to watchful waiting 4
- Competing mortality risks: At 74, other-cause mortality becomes increasingly relevant 5
What NOT to Do
Active surveillance is NOT recommended for this patient (Category 1 recommendation) 1, 6. This is explicitly contraindicated for intermediate-risk patients with life expectancy >10 years.
Brachytherapy monotherapy is NOT recommended for Gleason 7 disease. Risk stratification analysis shows brachytherapy alone is inferior to external beam RT or radical surgery for patients with Gleason pattern 4 or 5 cancer, or PSA >10 ng/mL 1.
ADT alone is insufficient and does not improve survival as primary treatment for localized disease 6.
Clinical Decision Algorithm
Confirm Gleason pattern (3+4 vs 4+3): While both require treatment, 4+3 has slightly worse prognosis 2, 3
Assess life expectancy and comorbidities:
Evaluate for high-risk features that might shift to high-risk category:
Patient preference assessment:
- If patient prioritizes avoiding surgery-related incontinence/erectile dysfunction: RT + ADT
- If patient has contraindications to RT or strong preference for surgery: Radical prostatectomy
Important Caveats
Staging workup required before treatment:
- Bone scan should be performed given PSA >10 4, 7
- Pelvic imaging (MRI or CT) if considering radical prostatectomy and predicted nodal involvement >2% 4
ADT side effects to discuss:
- Hot flashes, loss of libido, erectile dysfunction
- Metabolic effects (weight gain, insulin resistance)
- For bicalutamide monotherapy specifically: breast bud irradiation (8-10 Gy) should be given to prevent painful gynecomastia 4
Radiation technique is critical:
- Modern IMRT with daily IGRT is required, not older 2D techniques 1
- Dose escalation to 75-80 Gy improves biochemical control compared to conventional 70 Gy 1
The evidence strongly supports RT + short-term ADT as the optimal balance of efficacy and tolerability for this 74-year-old patient with intermediate-risk disease, providing cancer-specific survival benefit while minimizing treatment-related morbidity compared to surgery at this age.